Pulse Biosciences, Inc.
PLSENASDAQHealthcare● Active
$25.61
+$0.28(+1.12%)
Market Cap$1.8B
P/E Ratio—
52W High$27.98
52W Low$12.56
Pulse Biosciences, Inc. (PLSE) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
PLSE · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 4, 2026EPS Actual
-$0.27
Est. -$0.32 · +15.6%
Revenue
$0.00B
Est. $0.00B · +60.0%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 4, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 3-Quarter EPS Beat Streak
PLSE reports quarterly as a NASDAQ-listed Medical - Instruments & Supplies company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.36
Rev. $5.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.36
Rev. Est.$5.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 11, 2026 | -$0.31 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | May 4, 2026 | -$0.32 | -$0.27 | +15.6% | $0.00B | $0.00B | +60.0% |
| ▲ Q1 FY2026 | Feb 19, 2026 | -$0.27 | -$0.26 | +1.9% | $0.00B | $0.00B | +76.0% |
| ▲ Q4 FY2025 | Nov 5, 2025 | -$0.31 | -$0.29 | +6.5% | $0.00B | $0.00B | -61.8% |
| ▼ Q3 FY2025 | Aug 12, 2025 | -$0.26 | -$0.28 | -7.7% | — | $0.00B | — |
| — Q2 FY2025 | May 8, 2025 | — | -$0.17 | — | — | — | — |
| ▲ Q1 FY2025 | Mar 27, 2025 | -$0.24 | -$0.17 | +29.2% | $0.00B | — | — |
| ▲ Q4 FY2024 | Oct 30, 2024 | -$0.24 | -$0.16 | +33.3% | — | — | — |
Q3 FY2026
Aug 11, 2026
EPS Actual
—
EPS Est.
-$0.31
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 4, 2026Beat
EPS Actual
-$0.27
EPS Est.
-$0.32
EPS Surpr.
+15.6%
Revenue
$0.00B
Q1 FY2026
Feb 19, 2026Beat
EPS Actual
-$0.26
EPS Est.
-$0.27
EPS Surpr.
+1.9%
Revenue
$0.00B
Q4 FY2025
Nov 5, 2025Beat
EPS Actual
-$0.29
EPS Est.
-$0.31
EPS Surpr.
+6.5%
Revenue
$0.00B
Q3 FY2025
Aug 12, 2025Miss
EPS Actual
-$0.28
EPS Est.
-$0.26
EPS Surpr.
-7.7%
Revenue
—
Q2 FY2025
May 8, 2025
EPS Actual
-$0.17
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2025
Mar 27, 2025Beat
EPS Actual
-$0.17
EPS Est.
-$0.24
EPS Surpr.
+29.2%
Revenue
$0.00B
Q4 FY2024
Oct 30, 2024Beat
EPS Actual
-$0.16
EPS Est.
-$0.24
EPS Surpr.
+33.3%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.40 | $-0.36 | $-0.32 | 1 |
| Q3 FY2027 | $-0.40 | $-0.36 | $-0.32 | 1 |
| Q2 FY2027 | $-0.39 | $-0.35 | $-0.31 | 1 |
| Q1 FY2027 | $-0.39 | $-0.35 | $-0.31 | 1 |
| Q4 FY2026 | $-0.32 | $-0.29 | $-0.26 | 1 |
| Q3 FY2026 | $-0.33 | $-0.29 | $-0.26 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 4, 2026 | +15.6% | $20.83 | $20.03 | -3.84% |
| ▲ Q1 FY2026 | Feb 19, 2026 | +1.9% | $25.46 | $25.08 | -1.49% |
| ▲ Q4 FY2025 | Nov 5, 2025 | +6.5% | $16.06 | $16.27 | +1.31% |
| ▼ Q3 FY2025 | Aug 12, 2025 | -7.7% | $14.88 | $15.10 | +1.48% |
| — Q2 FY2025 | May 8, 2025 | — | $16.69 | $16.85 | +0.96% |
| ▲ Q1 FY2025 | Mar 27, 2025 | +29.2% | $15.80 | $15.66 | -0.89% |
| ▲ Q4 FY2024 | Oct 30, 2024 | +33.3% | $17.04 | $17.72 | +3.99% |
| ▲ Q3 FY2024 | Aug 12, 2024 | +16.7% | $15.65 | $15.65 | +0.00% |
Q2 FY2026-3.84%
Report Date
May 4, 2026
EPS Beat/Miss
+15.6%
Price Before
$20.83
Price After
$20.03
Q1 FY2026-1.49%
Report Date
Feb 19, 2026
EPS Beat/Miss
+1.9%
Price Before
$25.46
Price After
$25.08
Q4 FY2025+1.31%
Report Date
Nov 5, 2025
EPS Beat/Miss
+6.5%
Price Before
$16.06
Price After
$16.27
Q3 FY2025+1.48%
Report Date
Aug 12, 2025
EPS Beat/Miss
-7.7%
Price Before
$14.88
Price After
$15.10
Q2 FY2025+0.96%
Report Date
May 8, 2025
EPS Beat/Miss
—
Price Before
$16.69
Price After
$16.85
Q1 FY2025-0.89%
Report Date
Mar 27, 2025
EPS Beat/Miss
+29.2%
Price Before
$15.80
Price After
$15.66
Q4 FY2024+3.99%
Report Date
Oct 30, 2024
EPS Beat/Miss
+33.3%
Price Before
$17.04
Price After
$17.72
Q3 FY2024+0.00%
Report Date
Aug 12, 2024
EPS Beat/Miss
+16.7%
Price Before
$15.65
Price After
$15.65
Avg Beat Reaction-0.15%
Avg Miss Reaction+1.48%
Beat Rate6 / 8 quarters
Largest Move+3.99% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: PLSE ends December
Pulse Biosciences, Inc. (PLSE) most recently reported earnings on May 4, 2026 for Q2 FY2026, posting EPS of $-0.27 — beating the analyst consensus of $-0.32 by +15.6%. PLSE has beaten EPS estimates for 3 consecutive quarters. The next PLSE earnings date is expected around September 1, 2026.
Each quarter, investors track PLSE earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. PLSE revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
PLSE's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
PLSE earnings · 5 questionsPulse Biosciences, Inc.'s next earnings report is expected around September 1, 2026. PLSE typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; PLSE historically reports after market close (AMC).
PLSE earnings datewhen is PLSE earningsPLSE next earnings datewhen does PLSE report earningsPLSE earnings calendar
▸ Source: FMP · Pulse Biosciences, Inc. SEC filings · US GAAP · Pulse Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026